StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTI) stock

KPTINasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTIQ
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
$0.04−0.01 (-20.00%)

Close on Nov 9, 2026Market cap $1.16KP/E –Yield –

Karyopharm Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Karyopharm Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$82.35M. For fiscal 2025 it was -$90.71M. The highest annual figure on record is -$10.31M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$90.71M–
FY2024Dec 31, 2024-$119.44M–
FY2023Dec 31, 2023-$129.54M–
FY2022Dec 31, 2022-$142.20M–
FY2021Dec 31, 2021-$98.27M–
FY2020Dec 31, 2020-$171.85M–
FY2019Dec 31, 2019-$189.28M–
FY2018Dec 31, 2018-$179.88M–
FY2017Dec 31, 2017-$130.54M–
FY2016Dec 31, 2016-$110.73M–
FY2015Dec 31, 2015-$119.08M–
FY2014Dec 31, 2014-$75.85M–
FY2013Dec 31, 2013-$33.95M–
FY2012Dec 31, 2012-$15.89M–
FY2011Dec 31, 2011-$10.31M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$22.53M–
Q1 FY2026Mar 31, 2026-$26.76M–
Q4 FY2025Dec 31, 2025-$17.84M–
Q3 FY2025Sep 30, 2025-$15.22M–
Q2 FY2025Jun 30, 2025-$24.39M–
Q1 FY2025Mar 31, 2025-$33.26M–
Q4 FY2024Dec 31, 2024-$31.28M–
Q3 FY2024Sep 30, 2024-$26.28M–
Q2 FY2024Jun 30, 2024-$28.12M–
Q1 FY2024Mar 31, 2024-$33.76M–
Q4 FY2023Dec 31, 2023-$37.81M–
Q3 FY2023Sep 30, 2023-$31.26M–
Q2 FY2023Jun 30, 2023-$29.57M–
Q1 FY2023Mar 31, 2023-$30.90M–
Q4 FY2022Dec 31, 2022-$33.87M-172.1%
Q3 FY2022Sep 30, 2022-$30.84M–
Q2 FY2022Jun 30, 2022-$42.91M–
Q1 FY2022Mar 31, 2022-$34.59M–
Q4 FY2021Dec 31, 2021$46.96M–
Q3 FY2021Sep 30, 2021-$43.81M–
Q2 FY2021Jun 30, 2021-$49.05M–
Q1 FY2021Mar 31, 2021-$52.37M–
Q4 FY2020Dec 31, 2020-$37.07M–
Q3 FY2020Sep 30, 2020-$47.11M–
Q2 FY2020Jun 30, 2020-$40.32M–
Q1 FY2020Mar 31, 2020-$47.36M–
Q4 FY2019Dec 31, 2019-$43.27M–
Q3 FY2019Sep 30, 2019-$39.40M–
Q2 FY2019Jun 30, 2019-$41.69M–
Q1 FY2019Mar 31, 2019-$64.92M–
Q4 FY2018Dec 31, 2018-$57.46M–
Q3 FY2018Sep 30, 2018-$49.15M–
Q2 FY2018Jun 30, 2018-$34.33M–
Q1 FY2018Mar 31, 2018-$38.94M–
Q4 FY2017Dec 31, 2017-$39.45M–
Q3 FY2017Sep 30, 2017-$31.06M–
Q2 FY2017Jun 30, 2017-$29.75M–
Q1 FY2017Mar 31, 2017-$30.28M–
Q4 FY2016Dec 31, 2016-$27.17M–
Q3 FY2016Sep 30, 2016-$25.74M–

More Karyopharm Therapeutics figures

See a number that looks wrong?